Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.51 |
| ▸ | ARG2 | P78540 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | F10 | P00742 | 8/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594120 | 0.81 | MAPT (0.55) | CACNA1IKCNH2SIGMAR1L3MBTL1 | |
| SCHEMBL3594726 | 0.77 | HIF1A (0.46) | CACNA1IL3MBTL1 | |
| SCHEMBL3598760 | 0.77 | TP53 (0.44) | CACNA1IKCNH2 | |
| SCHEMBL3593611 | 0.76 | USP30 (0.50) | F10CACNA1IKCNH2L3MBTL1 | |
| SCHEMBL3937038 | 0.76 | CHRM4 (0.52) | ARG1ARG2EPHX2MAOAMAOB | |
| SCHEMBL3593975 | 0.76 | CCR5 (0.60) | ARG1ARG2MAOAMAOBSIGMAR1 | |
| SCHEMBL23123778 | 0.76 | CCR3 (0.61) | SIGMAR1 | |
| SCHEMBL3593316 | 0.76 | CCR2 (0.67) | CACNA1IKCNH2SIGMAR1 | |
| SCHEMBL2975028 | 0.76 | ARG1 (0.44) | ARG1ARG2EPHX2MAOAMAOB | |
| SCHEMBL3592322 | 0.75 | POLB (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | ARG1 3164/4885ARG2 3119/4885EPHX2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.